VivoSeq
Oncology

Haematological Malignancy

15

Pipeline Programs↗

2

Active Trials↗

7

Companies Involved↗

Haematological Malignancy is an emerging landscape with 15 programs across 7 companies. The most active players are Karuna Therapeutics, Inc., a Bristol Myers Squibb company, Roche, Johnson & Johnson.

Intelligence

Pipeline Metrics

Competitive Density

42/100

Pipeline Velocity

0/100

Mech. Concentration

15/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

K

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

3 programs

PreclinicalRoche logo

Roche

3 programs

PreclinicalJohnson & Johnson logo

Johnson & Johnson

2 programs

PreclinicalAbbVie logo

AbbVie

1 program

PreclinicalTakeda logo

Takeda

1 program

PreclinicalPfizer logo

Pfizer

1 program

Preclinical

Pipeline

Programs by Phase

Analysis

Modality Breakdown

73%

Small molecule

11 of 15 classified programs — the dominant modality here.

27%ALL OTHERSMonoclonal antibody427%

Small molecule leads; the ring shows all 15 classified programs, each share of the total. Modality classified for 83% of 18 pipeline programs.

Analysis

Trial Status

2

clinical trials

Recruiting2 · 100%

Clinical Trials

Trial Activity

DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial): An Umbrella-Basket Platform Trial to Evaluate the Efficacy of Targeted Therapies in Rare Adult, Paediatric and Teenage/Young Adult (TYA) Cancers With Actionable Genomic Alterations, Including Common Cancers With Rare Actionable Alterations
Recruiting·CCancer Research UK·Preclinical·NCT05722886·825 enrolled
An Open-label Phase I/IIa Study to Evaluate the Safety and Efficacy of CCS1477 as Monotherapy and in Combination in Patients With Advanced Haematological Malignancies.
Recruiting·CCellCentric Ltd.·Preclinical·NCT04068597·250 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)